Notice NOT-AG-18-032 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-054 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-19-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delivery, effectiveness of clinical decision-making and outcomes of treatments associated with dental, oral and craniofacial (DOC) tissues. Among the areas of interest of this FOA are development of digital imaging and image processing capabilities for dental radiology, and the integration of 3-dimensional (3D) additive manufacturing (e.g., 3D printing) with imaging tools. This FOA also supports efforts to develop, integrate, adapt, optimize, and validate new and existing dental materials designed for additive manufacturing approaches in the repair, replacement and restoration of DOC tissues.

Funding Opportunity PA-19-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages innovation, optimization and customization of core technologies in digital dentistry that improve efficiency of oral healthcare delivery, effectiveness of clinical decision-making and outcomes of treatments associated with dental, oral and craniofacial (DOC) tissues. Among the areas of interest of this FOA are development of digital imaging and image processing capabilities for dental radiology, and the integration of 3-dimensional (3D) additive manufacturing (e.g., 3D printing) with imaging tools. This FOA also supports efforts to develop, integrate, adapt, optimize, and validate new and existing dental materials designed for additive manufacturing approaches in the repair, replacement and restoration of DOC tissues.

Notice NOT-AT-19-002 from the NIH Guide for Grants and Contracts

Notice NOT-AT-19-003 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-013 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Lead Software Developer (Bioinformatics) A new opportunity is available for a talented Lead Bioinformatics Software Developer to join a growing start-up company based in Cambridge. Cambridge, England

Experience with RNA-sequencing and/or bioinformatics. The Department of Microbiology, Immunology and Cell biology is seeking applications for a Post Doctoral...
From West Virginia University - Mon, 08 Oct 2018 16:06:52 GMT - View all Morgantown, WV jobs

Negotiable: Paramount Recruitment: Rare Disease Analyst - Permanent 100,000 Genomes Project - Bioinformatics - Central London Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

The primary role of this position will focus on development of our genomics analysis software system....
From Resolution Bioscience - Fri, 05 Oct 2018 22:46:17 GMT - View all Redmond, WA jobs

Notice NOT-GM-19-002 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-059 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-019 from the NIH Guide for Grants and Contracts. This initiative will support exploratory and developmental multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.

Funding Opportunity PAR-19-018 from the NIH Guide for Grants and Contracts. This initiative will support multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.

Notice NOT-OD-19-012 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DE-19-006 from the NIH Guide for Grants and Contracts. The National Institute of Dental and Craniofacial Research (NIDCR) intends to continue support for research conducted within a national Dental Practice-Based Research Network (DPBRN). The NIDCR will fund one national DPBRN Administrative and Resource Center (RFA-DE-19-001) and one national DPBRN Coordinating Center (RFA-DE-19-002) as companion awards to support the infrastructure for and implementation of multiple observational studies and clinical trials. This Funding Opportunity Announcement (FOA) is soliciting applications for investigator-initiated clinical observational studies and clinical trials to be conducted in the DPBRN through a milestone-driven UG3/UH3 cooperative agreement mechanism. Each UG3/UH3 award will support an individual project which will utilize the DPBRN infrastructure and resources for study planning and implementation. This FOA supports a UG3 clinical study planning phase and potential transition to a UH3 implementation phase, with a combined total funding period of up to six years. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, consideration of the DPBRN as an appropriate venue for conduct of the research, NIDCR program priorities, and availability of funds. The main goals of the national DPBRN are to streamline the implementation of national oral health research studies in dental practices on topics of importance to practitioners and their patients, to provide evidence useful in daily patient care, and to facilitate the translation of research findings into clinical practice.

Funding Opportunity RFA-AI-18-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions and organizations to conduct research focused on elucidating mechanisms of Fc-dependent, antibody-mediated killing of infected or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. Studies supported by this FOA are expected to define variables that affect efficiencies of antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosis (ADCP), both in vitro and in vivo. U01 awardees will be expected to attend annual Program Progress/Steering Committee meetings and present progress to fellow awardees and to NIAID program staff. The goal of the meetings is to facilitate collaborations between funded investigators and to accelerate development of mechanistic models that incorporate the collective findings of this program. Advances in our understanding of these Fc-dependent killing mechanisms will inform more efficient design and optimization of ablative antibody therapeutics and may also inform design of vaccines that preferentially elicit ADCC- or ADCP-efficient antibody responses. This FOA uses the U01 grant mechanism, while the companion FOA, PA-19-xxx, uses the R21 mechanism. High risk/high reward projects with limited preliminary data or utilize existing data may be most appropriate for the R21 mechanism.

Funding Opportunity PA-19-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R21 applications for studies that address knowledge gaps in mechanisms of Fc-dependent, antibody-mediated killing of infected cells or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. More specifically, the purpose of this FOA is to promote innovative and exploratory research to elucidate mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), and to promote development of tools, technologies, and animal models to facilitate identification and evaluation of cytotoxic killing mechanisms mediated by human antibodies in vivo.

Funding Opportunity PAR-18-951 from the NIH Guide for Grants and Contracts. The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).